Spyre Therapeutics, Inc. (SYRE) Q1 2024 Earnings
SYRE·Reported May 9, 2024·Before market open
Diluted EPS came in at $-1.20, missed the $-0.90 consensus by $0.30.
Diluted EPS
$-1.20missed by $0.30
Consensus: $-0.90
Financial Snapshot
Trailing eight quarters through Q1 2024
Q1 2024 Earnings FAQ
Common questions about Spyre Therapeutics, Inc.'s Q1 2024 earnings report.
Spyre Therapeutics, Inc. (SYRE) reported Q1 2024 earnings on May 9, 2024 before market open.
Spyre Therapeutics, Inc. reported diluted EPS of $-1.20 for Q1 2024.
EPS missed the consensus estimate of $-0.90 by $0.30.
You can read the 10-Q periodic report (0001636282-24-000037) directly on SEC EDGAR. The filing index links above go to sec.gov.